FGF2 and cancer: This hypothesis is supported by the work of Dirix et al (1997), who have reported that the positive association of a short tumour volume-doubling time with elevated bFGF and VEGF serum levels in advanced cancer patients is largely independent from the metastatic pattern and the extent of the disease.